Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 1 to 39 of 39

TitleReference numberPublishedLast updated
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Bimekizumab for treating active psoriatic arthritisTA916
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768
Upadacitinib for treating moderate rheumatoid arthritisTA744
Tofacitinib for treating juvenile idiopathic arthritisTA735
Lateral elbow resurfacing for arthritisHTG591
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Upadacitinib for treating severe rheumatoid arthritisTA665
Rheumatoid arthritis in adults: managementNG100
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritisES29
Rheumatoid arthritis in over 16sQS33
Midcarpal hemiarthroplasty for wrist arthritisHTG529
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritisHTG521
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Total distal radioulnar joint replacement for symptomatic joint instability or arthritisHTG451
Sarilumab for moderate to severe rheumatoid arthritisTA485
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Baricitinib for moderate to severe rheumatoid arthritisTA466
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445
Ustekinumab for treating active psoriatic arthritisTA340
Apremilast for treating active psoriatic arthritisTA433
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hipTA304
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)TA302
Tocilizumab for the treatment of rheumatoid arthritisTA247
Tocilizumab for the treatment of systemic juvenile idiopathic arthritisTA238
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugsTA225
Golimumab for the treatment of psoriatic arthritisTA220
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritisTA199
Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritisHTG66

Results per page

  1. 10
  2. 25
  3. 50
  4. All